Investigating the Antiproliferative Activity of High Affinity DNA Aptamer on Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kaur, Harleen ^a   Li, Jasmine J ^a,b   Bay, Boon Huat ^b   Yung, Lin Yue Lanry ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; HEPARIN; JAGGED1; NOTCH RECEPTOR; PHOSPHOROTHIOIC ACID; VASCULOTROPIN 165;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CELL HYPOXIA; CELL PROLIFERATION; CHEMICAL MODIFICATION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE;

ANNEXIN A5; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL EXTRACTS; CELL PROLIFERATION; CIRCULAR DICHROISM; DEOXYRIBONUCLEASES; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HEP G2 CELLS; HUMANS; IMMOBILIZED PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; MEMBRANE PROTEINS; NEOPLASMS; ORGANOTHIOPHOSPHORUS COMPOUNDS; PROTEIN BINDING; SERUM; SURFACE PLASMON RESONANCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872442855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050964     Document Type: Article

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Intl J Cancer 127: 2893-2917.
2. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA-Cancer J Clin 61: 69-90.
3. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA-Cancer J Clin 60: 277-300.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W, (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J Med 350: 2335-2342.
6. Los M, Roodhart JML, Voest EE, (2007) Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450.
7. Leighl NB, Zatloukal P, Mezger J, Ramlau R, Moore N, et al. (2010) Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 5: 1970-1976.
8. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Eng J Med 349: 427-434.
9. Costa RB, Kurra G, Greenberg L, Geyer CE, (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21: 2153-2160.
10. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138-1144.
11. Wong SF, (2005) Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27: 684-694.
12. Frampton JE, (2010) Cetuximab: A review of its use in squamous cell carcinoma of the head and Neck. Drugs 70: 1987-2010.
13. Ellington AD, Szostak JW, (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
14. Tuerk C, Gold L, (1990) Systemic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
15. Jayasena SD, (1999) Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45: 1628-1650.
16. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO, (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86: 151-164.
17. Sayyed SG, Hägele H, Kulkarni OP, Endlich K, Segerer S, et al. (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52: 2445-2454.
18. Agrawal S, Temsamani J, Galbraith W, Tang J, (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28: 7-16.
19. Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, et al. (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 36: 831-841.
20. Vester B, Wengel J, (2004) LNA (Locked Nucleic Acid): High-affinity targeting of complementary RNA and DNA. Biochemistry 43: 13233-13241.
21. Lin Y, Nieuwlandt D, Magallanez A, Feistner B, Jayasena SD, (1996) High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA. Nucleic Acids Res 24: 3407-3414.
22. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, et al. (1998) 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556-20567.
23. Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, et al. (2005) Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem Biol 12: 25-33.
24. Boomer RM, Lewis SD, Healy JM, Kurz M, Wilson C, et al. (2005) Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides 15: 183-195.
25. de Smidt PC, Le Doan T, de Falco S, van Berkel TJC, (1991) Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res 19: 4695-4700.
26. Kang J, Lee MS, Copland JA III, Luxon BA, Gorenstein DG, (2008) Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-β1 protein. Bioorg Med Chem Lett 18: 1835-1839.
27. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
28. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M, (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Intl J Cancer 85: 27-34.
29. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H, (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12: 129-135.
30. Masood R, Cai J, Zheng T, Lynne Smith D, Hinton DR, et al. (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913.
31. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, et al. (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468-475.
32. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPH, et al. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846.
33. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH, (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
34. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343.
35. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, et al. (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24: 2647-2653.
36. Wey JS, Fan F, Gray MJ, Bauer TW, McCarty MF, et al. (2005) Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104: 427-438.
37. Kaur H, Yung L, (2012) Probing High Affinity Sequences of DNA aptamer against VEGF165. PLoS ONE 7: e31196.
38. Thiviyanathan V, Somasunderam AD, Gorenstein DG, (2007) Combinatorial selection and delivery of thioaptamers. Biochem Soc T 35: 50-52.
39. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N, (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037.
40. Robinson CJ, Stringer SE, (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853-865.
41. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, et al. (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788-7795.
42. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA, (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106: 18751-18756.
43. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, et al. (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176: 1375-1379.
44. Eaton BE, Gold L, Zichi DA, (1995) Let's get specific: The relationship between specificity and affinity. Chem Biol 2: 633-638.
45. Kypr J, Kejnovská I, Renčiuk D, Vorlíčková M, (2009) Circular dichroism and conformational polymorphism of DNA. Nucleic Acids Res 37: 1713-1725.
46. Suzuki H, Seto K, Shinoda Y, Mori M, Ishimura Y, et al. (1999) Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed Hep G2 cells. Am J Physiol Gastrointest Liver Physiol 276: G92-G97.
47. Oswald J, Treite F, Haase C, Kampfrath T, Mading P, et al. (2007) Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer lett 254: 102-110.
48. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G, (2008) Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 68: 285-291.
49. Radtke F, Raj K, (2003) The role of Notch in tumorigenesis: Oncogene or tumour suppressor. Nat Rev Cancer 3: 756-767.
50. Wang Z, Li Y, Banerjee S, Sarkar FH, (2008) Exploitation of the notch signaling pathway as a novel target for cancer therapy. Anticancer Res 28: 3621-3630.
51. Jiang X, Zhou JH, Deng ZH, Qu XH, Jiang HY, et al. (2007) Expression and significance of Notch1, Jagged1 and VEGF in human non-small cell lung cancer. J Cent South Univ 32: 1031-1036.
52. Thurston G, Kitajewski J, (2008) VEGF and Delta-Notch: Interacting signalling pathways in tumour angiogenesis. Brit J Cancer 99: 1204-1209.
53. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, et al. (2004) JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64: 6854-6857.
54. Gao J, Chen C, Hong L, Wang J, Du Y, et al. (2007) Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Co 356: 341-347.
55. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, et al. (2010) Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-κB signaling pathways. J Cell Biochem 109: 726-736.